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BACKGROUND: It has been suggested that the relative importance of oestrogen-metabolising pathways may affect the risk of
oestrogen-dependent tumours including endometrial cancer. One hypothesis is that the 2-hydroxy pathway is protective, whereas
the 16a-hydroxy pathway is harmful.
METHODS: We conducted a case–control study nested within three prospective cohorts to assess whether the circulating
2-hydroxyestrone : 16a-hydroxyestrone (2-OHE1 : 16a-OHE1) ratio is inversely associated with endometrial cancer risk in
postmenopausal women. A total of 179 cases and 336 controls, matching cases on cohort, age and date of blood donation,
were included. Levels of 2-OHE1 and 16a-OHE1 were measured using a monoclonal antibody-based enzyme assay.
RESULTS: Endometrial cancer risk increased with increasing levels of both metabolites, with odds ratios in the top tertiles of 2.4
(95% CI¼ 1.3, 4.6; Ptrend¼ 0.007) for 2-OHE1 and 1.9 (95% CI¼ 1.1, 3.5; Ptrend¼ 0.03) for 16a-OHE1 in analyses adjusting for
endometrial cancer risk factors. These associations were attenuated and no longer statistically significant after further adjustment for
oestrone or oestradiol levels. No significant association was observed for the 2-OHE1 : 16a-OHE1 ratio.
CONCLUSION: Our results do not support the hypothesis that greater metabolism of oestrogen via the 2-OH pathway, relative to the
16a-OH pathway, protects against endometrial cancer.
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The role of oestrogens in the development of endometrial cancer is
well documented by both experimental and epidemiologic studies
(Key and Pike, 1988; Akhmedkhanov et al, 2001). High oestrogen,
relative to progesterone/progestin, exposure leads to endometrial
hyperplasia, followed by atypical hyperplasia, the precursor of
most endometrial cancers (Sherman, 2000). In addition to
exogenous oestrogens (Grady et al, 1995), circulating levels of
endogenous oestrogens in postmenopausal women have been
shown to be positively associated with risk of endometrial cancer
in prospective studies (Zeleniuch-Jacquotte et al, 2001; Lukanova
et al, 2004; Allen et al, 2008). Oestrogens are metabolised through
various pathways, and it has been suggested that the relative
importance of these pathways within an individual may affect the
risk of oestrogen-dependent tumours, such as breast and
endometrial cancers (Fishman et al, 1984; Zhu and Conney,
1998). One specific hypothesis is that the 2-hydroxyestrogen
metabolite pathway is protective, whereas the 16a-hydroxyestro-
gen pathway is harmful (Schneider et al, 1982; Fishman et al, 1984;
Sepkovic and Bradlow, 2009). The basis for this hypothesis is that
2-hydroxyestrogens bind to oestrogen receptors but do not
activate transcription, resulting in no or limited proliferative
effects, whereas 16a-hydroxyestrogens have prolonged oestrogenic
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effects including stimulation of cell proliferation (Sepkovic and
Bradlow, 2009).
A number of prospective studies have examined the effects of
2-hydroxyestrone (2-OHE1), 16a-hydroxyestrone (16a-OHE1) and
their ratio in relation to risk of breast cancer with inconsistent
results (Meilahn et al, 1998; Muti et al, 2000; Cauley et al, 2003;
Wellejus et al, 2005; Modugno et al, 2006; Eliassen et al, 2008;
Arslan et al, 2009). No study, though, has been conducted in
relation to endometrial cancer risk. We conducted a case– control
study nested within three prospective cohorts to test the
hypothesis that the circulating 2-OHE1 : 16a-OHE1 ratio, an index
of the relative importance of the 2-OH and 16a-OH oestrogen
pathways, is inversely associated with risk of endometrial cancer in
postmenopausal women. We previously reported positive associa-
tions between postmenopausal circulating oestrogens and andro-
gens and risk of endometrial cancer in a subset of the subjects
included in this study (Lukanova et al, 2004).
MATERIALS AND METHODS
Study population and biological sample collection
The case–control study was nested within three cohorts: the
Northern Sweden Disease and Health Study (NSHDS) in Umea˚,
Sweden (Hulten et al, 2001), the New York University Women’s
Health Study (NYUWHS) in New York City, NY, USA (Toniolo
et al, 1995; Zeleniuch-Jacquotte et al, 2001) and the ORDET cohort
in Milan, Italy (Muti et al, 2000; Sieri et al, 2009). The recruitment
setting, eligibility criteria and case ascertainment methods for each
cohort are described in Table 1. As described in Lukanova et al
(2004), data on known risk factors for endometrial cancer were
obtained at enrolment through interviews by nurses for ORDET
and by a combination of self-administered baseline and follow-up
questionnaires for the NSHDS and the NYUWHS. Height and
weight were self-reported for the NSHDS and the NYUWHS and
measured by nurses for ORDET at enrolment. Venous blood was
collected at enrolment (plasma for the NSHDS, serum for the
NYUWHS and both plasma and serum for ORDET). All specimens
were stored at 801C by the respective cohorts. The Institutional
Review Boards of New York University School of Medicine and of
the Istituto Nazionale dei Tumori in Milan and the Regional
Ethical Committee of the University of Umea˚, Sweden, reviewed
and approved this study. Informed consent was obtained from all
participants at enrolment.
Menopausal status was determined at enrolment for the
NYUWHS and ORDET participants. Women were classified as
postmenopausal if they had not had menstrual periods for at least
6 months (NYUWHS) or 12 months (ORDET). In the NYUWHS,
women who had had a total oophorectomy and women who had
had a hysterectomy without total oophorectomy and were 52 years
old or older were also classified as postmenopausal. In ORDET,
women who had had a bilateral oophorectomy were not eligible to
enter the cohort. For NSHDS cases and controls, menopausal
status at enrolment was determined retrospectively based on
reported age at menopause on baseline or case–control ques-
tionnaires. In addition, FSH measurements were used for all
women between the ages of 46 and 57 years. Women were
classified as postmenopausal if they had FSH levels 420 IU l1 and
their questionnaire data were consistent with postmenopausal
status. Finally, women taking hormone replacement therapy
(HRT) in the three (ORDET), or six (NSHDS, NYUWHS), months
before enrolment were not included.
Case ascertainment and control selection
Case subjects were women who were postmenopausal at enrolment
and diagnosed with invasive endometrial cancer (ICD-O codes
8010, 8140, 8210, 8260, 8310, 8323, 8380, 8382, 8441, 8460, 8461,
8480, 8481, 8560 and 8570) after enrolment and before 1 January
2007 for the NSHDS, 1 July 2003 for the NYUWHS and 1 January
2004 for ORDET. Cases who had been diagnosed with another
cancer (except non-melanoma skin cancer) before endometrial
cancer were not eligible.
For each case, two controls were selected at random from the
appropriate risk set, which consisted of all women with an intact
uterus and free of cancer at the date of diagnosis of the case and
matching the case on cohort, menopausal status at enrolment, age
(±6 months) at, and date (±3 months) of, blood donation.
Laboratory analyses
All oestrogen metabolite assays were conducted in the same
laboratory, Immuna Care Corporation, (Tampa, FL, USA), using
monoclonal antibody-based enzyme assays (ESTRAMET 2/16,
Immuna Care Corporation). The enzyme immunoassays (EIAs)
were developed for urinary samples (Klug et al, 1994; Falk et al,
2000) and validated against gas chromatography –mass spectro-
metry (GC– MS) (Falk et al, 2000). They were validated for serum
by conducting the assays on pooled human serum samples to
Table 1 Description of the cohorts
Cohort
Cohort size (age at
enrolment, years)
Recruitment
(enrolment period) Data collection
Case ascertainment
methods
Number of
cases/controls
NSHDS Umea˚,
Sweden
485 000 men and women
(30–70)
General population,
Va¨sterbotten County
(1985–present)
Questionnaire at enrolment;
data on reproductive life and
hormone use updated by
case–control questionnaire
Linkage to the Swedish
Cancer Registry
89/164
NYUWHS New York
City, NY, USA
14 274 women, no current
use of OC or HRT
(35–65)
Breast cancer screening
centre (1985–1991)
Questionnaire at enrolment;
prospective follow-up
questionnaires; and case–
control interview for
reproductive life and hormone
use
Follow-up
questionnaires and
linkages to state
tumour registries (NY,
NJ, FL) and the NDI
75/143
ORDET Milan, Italy 10 788 women, no current
use of OC or HRT and
no total oophorectomy
(35–69)
General population, Varese
Province (1987–1992)
Interview at enrolment Linkage to the
Lombardy Cancer
Registry
15/29
Abbreviations: OC¼ oral contraceptives; HRT¼ hormone replacement therapy; NDI¼ national death index; NSHDS¼Northern Sweden Disease and Health Study;
NYUWHS¼ New York University Women’s Health Study.
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which known amounts of 2-OHE1 and 16a-OHE1 had been added
(Klug, personal communication). Serum samples were used for the
NYUWHS and ORDET, and EDTA-plasma samples for the NSHDS.
Assay variability was assessed by including 10% blinded quality
control samples (samples from a pool for the NSHDS and
duplicates for the NYUWHS). For serum, the within- and
between-batch coefficients of variation were 4% and 6% for
2-OHE1 and 1% and 2% for 16a-OHE1, respectively. For EDTA-
plasma, the within- and between-batch coefficients of variation
were 2% and 2% for 2-OHE1 and 1% and 4% for 16a-OHE1,
respectively.
As described previously (Lukanova et al, 2004), oestrone and
oestradiol were measured by a radioimmunoassay following
organic extraction and celite chromatography for 129 (76%) of
the NYUWHS samples. For all other samples, oestrone was
measured by double antibody RIA and oestradiol by ultrasensitive
double antibody RIA with reagents from Diagnostic Systems
Laboratories (Webster, TX, USA).
Statistical methods
The intra-class correlation coefficient (Donner, 1986) was used to
assess the temporal reliability of the oestrogen metabolites and
their ratio in a pilot study where oestrogen metabolites were
measured in three serum samples collected at approximately yearly
intervals in 30 NYUWHS participants postmenopausal at blood
donation and free of cancer at latest follow-up.
Because serum was used for the NYUWHS and the ORDET
cohorts and EDTA plasma for the NSHDS, a substudy was
conducted to compare levels of oestrogen metabolites in serum
with levels in EDTA-plasma samples collected at the same visit from
17 NSHDS participants. We found that plasma samples led to much
higher values than serum samples: for 2-OHE1 the median was
526 pg ml1 using plasma and 183 pg ml1 using serum, and for 16a-
OHE1 the median was 618 pg ml1 using plasma and 518 pg ml1
using serum. The median 2-OHE1 : 16a-OHE1 ratio was 1.06 using
plasma samples and 0.43 using serum samples. Although the
absolute values were quite different, the Pearson correlation
coefficients were high between plasma and serum levels (0.96 for
2-OHE1, 0.99 for 16a-OHE1 and 0.81 for the 2-OHE1 : 16a-OHE1
ratio). Further analyses showed that serum levels (on the natural
logarithmic scale) of metabolites could be accurately predicted from
plasma levels (also on the logarithmic scale) using a linear
regression model (R2¼ 0.85 for 2-OHE1 and 0.99 for 16a-OHE1).
The observed serum 2-OHE1 : 16a-OHE1 ratio was slightly more
strongly correlated (r¼ 0.86) with the predicted serum ratio
(calculated as the ratio of the predicted serum 2-OHE1 and 16a-
OHE1 levels) than with the plasma ratio (r¼ 0.81). Therefore, and
in order to facilitate the combination of the data from the three
cohorts as well as the interpretation of the results, we used predicted
serum values for the NSHDS participants in all analyses. To predict
the serum levels of 2-OHE1 and 16a-OHE1 from the plasma levels
for the NSHDS samples, we created 10 imputed data sets using a
multiple imputation procedure with the linear regression models
fitted in the substudy. We then calculated the serum 2-OHE1 : 16a-
OHE1 ratio using the imputed serum levels of 2-OHE1 and 16a-
OHE1. The SAS PROC MI and MIANALYZE in SAS 9.2 were used
(SAS Institute, Inc., Cary, NC, USA).
The conditional logistic regression model was used to take into
account the matched design. The analysis was conducted after
classifying participants according to cohort-specific metabolite
tertiles using the distribution of cases and controls combined. The
lowest tertile was used as reference. Because analyses were
conducted using 10 imputed data sets, the means of the odds
ratio estimates are reported. The within-imputation variance and
between-imputation variances were calculated and combined to
yield the total variance using Rubin’s method (Rubin, 1987). The
95% confidence intervals and P-values were then calculated using
the t-distribution (SAS PROC MI and MIANALYZE). In addition to
analyses by tertiles, analyses were conducted with the oestrogen
metabolites and their ratio on the continuous (log transformed)
scale. The log2 transformation, which leads to an odds ratio for a
doubling in level, was used.
The following known endometrial cancer risk factors were
considered as potential confounders: age at menarche, parity, OC
use, HRT use, body mass index (BMI) and smoking. Analyses
adjusting simultaneously for all these variables are presented in
addition to unadjusted analyses. Analyses stratified by age at
sampling (o60 and X60 years), age at diagnosis (o65 and X65
years), lag time between blood donation and diagnosis (o7 and
X7 years) and BMI (o25 and X25 kg m2) were also conducted.
Interaction tests were conducted to assess whether the associations
of the oestrogen metabolites or their ratio with endometrial cancer
risk varied according to strata of these factors. We also assessed
whether the oestrogen metabolite –endometrial cancer risk asso-
ciations differed by cohort.
RESULTS
The ICC measuring the temporal reliability over a 2-year period
was 0.62 (95% CI¼ 0.42, 0.78) for 2-OHE1, 0.95 (95% CI¼ 0.91,
0.97) for 16a-OHE1 and 0.69 (95% CI¼ 0.52, 0.82) for their ratio.
These results were quite similar to those observed by Eliassen et al
who reported intra-class correlation coefficients of 0.63 for
2-OHE1, 0.80 for 16a-OHE1 and 0.73 for their ratio, indicating that
a single measurement can be used as a marker of average exposure to
these metabolites in epidemiologic studies (Eliassen et al, 2008).
A total of 179 cases and 336 controls were included (89 cases
and 164 controls from the NSHDS, 75 cases and 143 controls
from the NYUWHS and 15 cases and 29 controls from ORDET).
Table 2 reports on the case and control subject characteristics.
The median age at blood donation was 59.9 years and at diagnosis
66.5 years. The vast majority of participants (94% of cases and
97% of controls) were Caucasians. Associations with known risk
factors for endometrial cancer were in the expected directions.
Compared with controls, cases had younger age at menarche and
older age at menopause, and were heavier. Cases were more likely
than controls to have used HRT but less likely to have used oral
contraceptives and to have ever smoked. Levels of both oestrogen
metabolites were significantly higher in cases than in controls,
whereas the 2-OHE1 : 16a-OHE1 ratio was not statistically different
in cases and controls.
The 2-OHE1 and 16a-OHE1 were moderately correlated with
each other (cohort- and age-adjusted Spearman correlation
r¼ 0.20 in controls and 0.19 in cases). The 2-OHE1 : 16a-OHE1
ratio was strongly correlated with levels of 2-OHE1 (r¼ 0.85 in
controls and 0.87 in cases) and negatively, but less strongly,
correlated with 16a-OHE1 (r¼0.30 in controls and 0.26 in
cases). Correlations were low between oestrone and 2-OHE1
(r¼ 0.13 in controls and 0.19 in cases), 16a-OHE1 (r¼ 0.15 in
controls and 0.21 in cases) and their ratio (r¼ 0.03 in controls and
0.10 in cases). Correlations of the oestrogen metabolites and their
ratio with oestradiol were in the same direction as with oestrone
but weaker (data not shown).
Table 3 reports odds ratios for the associations of the two
oestrogen metabolites and their ratio, with risk of endometrial
cancer. In unadjusted analyses, the risk of endometrial cancer
increased significantly with increasing tertiles of 2-OHE1 and
16a-OHE1. The associations remained significant after adjusting
for known endometrial cancer risk factors, with odds ratios in the
top tertile of 2.4 (95% CI¼ 1.3–4.6; Ptrend¼ 0.007) for 2-OHE1 and
1.9 (95% CI¼ 1.1– 3.5; Ptrend¼ 0.03) for 16a-OHE1. Although the
odds ratios in the top two tertiles were somewhat elevated, no
significant association was observed with the 2-OHE1 : 16a-OHE1
ratio in unadjusted, as well as in adjusted, analyses.
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Table 3 ORs and 95% CIs for endometrial cancer according to circulating levels of 2-OHE1, 16a-OHE1 and the 2-OHE1 : 16a-OHE1 ratio
Tertiles
Oestrogen metabolites 1 2 3 Ptrend
2-OHE1
Cases/controls 45/125 61/112 73/99
Crude OR (95% CI) 1.00 (reference) 1.55 (0.89, 2.70) 2.24 (1.28, 3.91) 0.005
Multivariate OR (95% CI)a 1.00 (reference) 1.87 (0.98, 3.55) 2.41 (1.27, 4.58) 0.007
16a-OHE1
Cases/controls 44/127 66/107 69/102
Crude OR (95% CI) 1.00 (reference) 1.71 (1.01, 2.91) 2.01 (1.21, 3.35) 0.007
Multivariate OR (95% CI)a 1.00 (reference) 2.06 (1.14, 3.70) 1.89 (1.05, 3.41) 0.03
2-OHE1 : 16a-OHE1 ratio
Cases/controls 49/121 69/104 61/111
Crude OR (95% CI) 1.00 (reference) 1.56 (0.92, 2.66) 1.34 (0.78, 2.31) 0.28
Multivariate OR (95% CI)a 1.00 (reference) 1.74 (0.95, 3.20) 1.33 (0.73, 2.44) 0.35
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; OR¼ odds ratio; 16a-OHE1¼ 16a-hydroxyestrone; 2-OHE1¼ 2-hydroxyestrone. aAdjusted for age at
menarche (o12, 12, 13, 413 years and missing), age at menopause (o50, 50-52, 452 years and missing), parity (ever, never and missing), oral contraceptive use (ever, never
and missing), hormone replacement therapy use (ever, never and missing), smoking (ever, never and missing) and BMI (o25, 25–30, X30 kg m2 and missing).
Table 2 Description of case and control subjects
Cases (n¼ 179) Controls (n¼ 336)
Characteristic N % Median (10th, 90th) N % Median (10th, 90th) P-value
Age at blood donation, years 59.9 (51.6, 65.4) 59.9 (51.8, 65.4) Matched
Age at diagnosis, years 66.5 (58.9, 73.8)
Lag time between blood donation and diagnosis 7.3 (1.9–13.0)
Race 0.41
Caucasian 163 94 312 97
Other 11 6 13 3
Missing 5 11
Height, cm 162.6 (154.0, 170.2) 161.5 (154.0, 169.0) 0.49
Weight, kg 71.3 (55.0, 94.0) 65.8 (54.4, 84.4) o0.0001
Body mass index, kgm2 0.001
o25 53 34 154 50
25-o30 57 37 101 33
X30 46 29 54 17
Missing, n 23 27
Age at menarche, years 0.01
o12 33 19 33 10
12–13 82 46 161 49
413 61 35 132 41
Missing, n 3 10
Age at menopause, years 51.5 (46.0, 56.0) 50.0 (45.0, 55.0) 0.004
Missing, n 23 43
Nulliparous 29 16 58 18 0.70
Missing, n 0 5
Ever used OC 33 19 75 23 0.05
Missing, n 7 13
Ever used HRT 59 37 80 26 0.01
Missing, n 23 27
Ever smoked 57 34 134 42 0.09
Missing, n 12 17
History of diabetes 13 8 17 5 0.54
Missing, n 10 11
2-OHE1 (pg ml1) 130.2 (67.0–221.4) 113.5 (61.3, 208.3) 0.03
16a-OHE1 (pg ml1) 335.3 (255.0, 460.2) 314.0 (225.6, 436.9) 0.02
2-OHE1 : 16a-OHE1 ratio 0.40 (0.19, 0.69) 0.37 (0.19, 0.70) 0.58
Abbreviations: OC¼ oral contraceptives; HRT¼ hormone replacement therapy; 16a-OHE1¼ 16a-hydroxyestrone; 2-OHE1¼ 2-hydroxyestrone.
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Table 4 shows odds ratios for endometrial cancer risk associated
with a doubling in levels of each of the two oestrogen metabolites
and of their ratio, for all subjects included in the study as well as
for the subset of 101 cases and 183 controls for whom oestrone and
oestradiol measurements were available. Overall results were
similar in the two groups, that is significant trends of increasing
risk with increasing levels of 2-OHE1 and 16a-OHE1 and no
association with the ratio, although odds ratios for 2-OHE1 and
16a-OHE1 were slightly higher in the subgroup than in the whole-
group analyses. The table also shows that adjusting for either
oestrone or oestradiol, in addition to adjusting for known risk
factors, resulted in an attenuation of the odds ratios associated
with 2-OHE1 and 16a-OHE1, which were no longer statistically
significant. On the other hand, the strong associations of oestrone
and oestradiol with endometrial cancer risk remained highly
significant after adjusting for the two oestrogen metabolites.
Results in analyses limited to the 142 sets whose case subject had
an endometrioid-type tumour were similar to the overall results
(data not shown). There was no evidence of heterogeneity by
cohort in any of the analyses. There was also no evidence of effect
modification by age at blood donation, age at diagnosis, lag time
between blood donation and diagnosis or BMI.
DISCUSSION
Contrary to our hypothesis, women with a higher 2-OHE1 : 16a-
OHE1 ratio did not have a decreased risk of endometrial cancer as
compared with women with a lower ratio. Regarding absolute
levels of 2-OHE1 and 16a-OHE1, we found that both were directly
associated with risk in unadjusted analyses as well as in analyses
adjusting for known risk factors of endometrial cancer. These
associations, though, were no longer significant after adjusting for
oestrone, which is positively associated with both risk of
endometrial cancer (Lukanova et al, 2004; Allen et al, 2008) and
levels of metabolites, and therefore a positive confounder. Similar
results were observed when adjusting for oestradiol, a more potent
oestrogen than oestrone. On the other hand, the odds ratios
associated with the 2-OHE1 : 16a-OHE1 ratio were not materially
affected by adjustment for oestrone. This was not surprising, as
the ratio was not correlated with the level of oestrone,
which confirmed that the ratio is an index of the relative
importance of these two metabolic pathways independent of the
levels of oestrone.
The findings from this first prospective epidemiological study of
oestrogen metabolites and endometrial cancer are in line with
results from prospective studies on breast cancer, another
oestrogen-related cancer. None of the seven studies on breast
cancer reported significant associations overall (Meilahn et al,
1998; Muti et al, 2000; Cauley et al, 2003; Wellejus et al, 2005;
Modugno et al, 2006; Eliassen et al, 2008; Arslan et al, 2009). Some
studies reported significant associations in subgroups, but the
subgroup results were not consistent across studies (Eliassen et al,
2008). On the whole, prospective epidemiological data do not
support the hypothesis that the 2-hydroxyestrogen pathway is
protective, and the 16a-hydroxyestrogen pathway harmful, in
hormone-dependent cancers.
Although no longer significant, odds ratios associated with
2-OHE1 remained somewhat elevated after adjusting for oestrone
or oestradiol. It is possible that these elevations were due to
remaining confounding by the main oestrogens affecting endome-
trial cancer, that is, oestrone and oestradiol. However, a significant
increase in risk of breast cancer with levels of 2-OHE1 has also been
reported previously, although it was limited to hormone receptor-
negative tumours (Eliassen et al, 2008). Although there is a
substantial amount of experimental data supporting the hypothesis
that the 2-hydroxyestrogen pathway may be protective against
oestrogen-driven cancers, not all studies agree. One study showed
that uterine adenocarcinomas were induced in CD-1 mice by both
2-hydroxyestradiol and 4-hydroxyestradiol (Newbold and Liehr,
2000). Both 2- and 4-hydroxyestrogens are catecholestrogens, and
it has been suggested that catecholestrogens increase risk of
oestrogen-mediated cancers through direct genotoxic effects,
rather than through stimulation of cell proliferation via binding
to oestrogen receptors (Jefcoate et al, 2000; Yager, 2000; Liehr and
Jones, 2001; Cavalieri et al, 2002). Although the evidence is
stronger for 4-hydroxyestrogens than for 2-hydroxyestrogens
(Gaikwad et al, 2008), the hypothesis that catecholestrogens,
Table 4 Odds ratios associated with a doubling in levels of circulating oestrogens, oestrogen metabolites and 2-OHE1 : 16a-OHE1 ratio
Model Oestrone Oestradiol 2-OHE1 16a-OHE1
2-OHE1 : 16a-OHE1
ratio
All subjects
Adjusted for known risk factorsa
OR (95% CI) 1.39 (1.01, 1.90) 1.73 (1.05, 2.85) 1.05 (0.50, 2.20)
P-value 0.04 0.03 0.90
Subjects with oestrogen measurements
Adjusted for known risk factorsa
OR (95% CI) 2.25 (1.36, 3.71) 2.51 (1.57, 4.02) 1.76 (1.07, 2.92) 1.92 (0.93, 3.96) 1.07 (0.41, 2.81)
P-value 0.002 0.0001 0.03 0.08 0.89
Adjusted for known risk factors, 2-OHE1 and 16a-OHE1a
OR (95% CI) 1.98 (1.18, 3.32) 2.26 (1.40, 3.66)
P-value 0.009 0.001
Adjusted for known risk factors and oestronea
OR (95% CI) 1.51 (0.89, 2.55) 1.58 (0.80, 3.15) 1.00 (0.37, 2.73)
P-value 0.13 0.19 0.99
Adjusted for known risk factors and oestradiola
OR (95% CI) 1.51 (0.89, 2.57) 1.59 (0.79, 3.22) 1.04 (0.37, 2.91)
P-value 0.12 0.19 0.94
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; OR¼ odds ratio; 16a-OHE1¼ 16a-hydroxyestrone; 2-OHE1¼ 2-hydroxyestrone. aAge at menarche (o12, 12,
13, 413 years and missing), age at menopause (o50, 50–52, 452 years and missing), parity (ever, never and missing), oral contraceptive use (ever, never and missing),
hormone replacement therapy use (ever, never and missing), smoking (ever, never and missing), and BMI (o25, 25–30, X30 kg m2 and missing).
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including 2-hydroxyestrogens, increase risk of endometrial cancer
deserves to be evaluated. Further, oestrogen can be metabolised
through other pathways. New methods are now available to
measure a broad range of oestrogen metabolites (Xu et al, 2005,
2007), which may help assess the role of various pathways in the
development of breast and endometrial cancers.
Strengths of our study include its prospective design, with blood
samples collected before diagnosis, and the results of our pilot
study, which showed that oestrogen metabolites had good
temporal reliability in our population, indicating that a single
measurement reflects reasonably well a woman’s average level over
several years, relative to other women. Associations with known
risk factors for endometrial cancer were observed in our study.
Finally, in addition to adjusting for these known risk factors, we
were able to control for circulating levels of the two main
oestrogens, that is, oestrone and oestradiol.
Our study also has some limitations. First, the specificity and
accuracy of the EIAs assays have been recently questioned (Faupel
Badger et al, 2010). An early study comparing the EIAs with GC–
MS for urinary samples from postmenopausal women had showed
high correlations between the two methods for 2-OHE1, 16a-OHE1
and their ratio (Spearman correlation coefficients X0.70; Falk et al,
2000). A recent, much larger study, though, found that in
postmenopausal women the mean urinary concentration of
2-OHE1 was 6-fold higher, and that of 16a-OHE1 12-fold higher
when measured by the EIAs than when measured using liquid
chromatography–tandem mass spectrometry (LC–MS/MS).
Further, the Spearman correlation coefficients for the ratio based
on the two methods were only 0.17 for the 2-OHE1 : 16a-OHE1 ratio
and 0.25 for the 2-pathway : 16a-pathway ratio (Faupel Badger,
Fuhrman et al, 2010). Although these correlations are weak,
suggesting limited specificity of the EIA assays, it is unlikely that
we would have observed an inverse association between the
2-OHE1 : 16a-OHE1 ratio and endometrial cancer risk if we had
used LC–MS/MS rather than EIAs because, although not signifi-
cant, we observed a positive association between the EIA ratio and
risk of endometrial cancer and because the correlation of the ratio
estimates obtained by the two methods is positive.
Another limitation of our study is that concentrations of
oestrogen metabolites were higher when measured in EDTA
plasma (for the NSHDS) than when measured in serum (for
the NYUWHS and ORDET) samples. Several reasons may
have contributed to the higher concentrations observed with
EDTA-plasma samples, such as binding of EDTA with cations
(e.g., calcium) which are cofactors in the stabilisation of the
enzymes used in assay (e.g., alkaline phosphatase) and differences
in protein composition. Because the validation study we conducted
showed that serum concentrations could be accurately predicted
from plasma concentrations in Swedish participants for whom
EDTA-plasma and serum samples collected at the same time were
available, we predicted serum values for the NSHDS participants
and presented results combining the three cohorts. It should be
noted that analyses conducted within each cohort separately
showed similar results, suggesting that the type of samples did not
affect the conclusions.
In conclusion, our results do not support the hypothesis that
greater metabolism of oestrogen via the 2-OH pathway, relative to
the 16a-OH pathway, protects against endometrial cancer. Indeed
our results are more suggestive of an increase in risk, rather than a
decrease, with higher levels of 2-OHE1. Assays measuring a broad
panel of oestrogen metabolites, including catecholestrogens,
should be used in future studies to assess the role of various
oestrogen metabolic pathways in the development of oestrogen-
related cancers.
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